Australia markets open in 8 hours 16 minutes

MyMD Pharmaceuticals, Inc. (MYMD)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.8400-0.0200 (-1.08%)
As of 11:39AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close1.8600
Open1.8500
Bid1.7800 x 100
Ask0.0000 x 0
Day's range1.8200 - 1.8800
52-week range1.8000 - 63.9000
Volume28,251
Avg. volume245,303
Market cap4.246M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-9.2700
Earnings date29 Mar 2024 - 02 Apr 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    MyMD Pharmaceuticals Secures Strategic Investments

    BALTIMORE, May 21, 2024--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, and autoimmune and inflammatory conditions, today announced that it has secured $7 million in commitments in two private placement funding rounds led by a strategic investor, PharmaCyte Biotech, Inc. (Nasdaq: PMCB), a clinical-stage biotechnology company developing cellular therapies for cancer

  • Business Wire

    MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

    BALTIMORE, March 05, 2024--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, today announced that it received notice from The Nasdaq Stock Market LLC ("Nasdaq") on March 4, 2024 informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) ("Listing Rule") for co

  • Business Wire

    MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

    BALTIMORE, February 13, 2024--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced today that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 30 pre-split shares. The reverse stock split will become effective at 4:05 p.m. Eastern Standard Time on Wednesday, February